1. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations – Still a daily challenge
   Chunxia Su et al, 2017, European Journal of Cancer CrossRef
2. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
   David R. Spigel et al, 2019, Journal of Thoracic Oncology CrossRef
3. Identification of epithelial-mesenchymal transition-related biomarkers in lung adenocarcinoma using bioinformatics and lab experiments
   Yuanjun Cheng et al, 2023, Aging CrossRef
4. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials
   Ruifeng Liu et al, 2019, Medicine CrossRef
5. Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
   Rolof GP Gijtenbeek et al, 2019, Cochrane Database of Systematic Reviews CrossRef
6. Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
   Didier Debieuvre et al, 2021, Lung Cancer CrossRef
7. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
   null null et al, 2023, Cochrane Database of Systematic Reviews CrossRef
8. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater
   Takayuki Jodai et al, 2021, International Journal of Clinical Oncology CrossRef
9. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States
   David D. Stenehjem et al, 2021, Clinical Lung Cancer CrossRef
10. IL-17F expression correlates with clinicopathologic factors and biological markers in non-small cell lung cancer
    Chun Li et al, 2019, Pathology - Research and Practice CrossRef
11. Trial watch: DNA-based vaccines for oncological indications
    Stefano Pierini et al, 2017, OncoImmunology CrossRef
12. Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center
    D. I. Yudin et al, 2021, Meditsinskiy sovet = Medical Council CrossRef
13. FOXP3 facilitates the invasion and metastasis of non‑small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway
    Chun Li et al, 2021, Experimental and Therapeutic Medicine CrossRef
14. miR‑379 inhibits cell proliferation and epithelial‑mesenchymal transition by targeting CHUK through the NF‑κB pathway in non‑small cell lung cancer
    Bin Liu et al, 2019, Molecular Medicine Reports CrossRef
15. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer
    Lan Shen et al, 2017, Lung Cancer CrossRef
16. HSP90B1 overexpression predicts poor prognosis in NSCLC patients
    YiRong Xu et al, 2016, Tumor Biology CrossRef
17. Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment
    David J. Stewart et al, 2019, Cancer Medicine CrossRef
18. Fentanyl induces autophagy via activation of the ROS/MAPK pathway and reduces the sensitivity of cisplatin in lung cancer cells
    Jiaqi Yao et al, 2016, Oncology Reports CrossRef